KNSA vs IMVT

Kiniksa Pharmaceuticals, Ltd.

(KNSA) offers the better valuation at 77. 6x trailing P/E (42. 5x forward), making it the more compelling value choice. Analysts rate Kiniksa Pharmaceuticals, Ltd. (KNSA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kiniksa Pharmaceuticals, Ltd.

(KNSA) delivered a total return of +298. 3%, compared to +73. 9% for Immunovant, Inc. (IMVT). Over 10 years, the gap is even starker: KNSA returned +199. 1% versus IMVT's +188. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Kiniksa Pharmaceuticals, Ltd.

(KNSA) is the lower-risk stock at 0. 19β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 616% more volatile than KNSA relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for Kiniksa Pharmaceuticals, Ltd. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Kiniksa Pharmaceuticals, Ltd.

grew EPS 225. 0% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Kiniksa Pharmaceuticals, Ltd.

(KNSA) is the more profitable company, earning 8. 7% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 8. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KNSA leads at 11. 4% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — KNSA leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for IMVT: 58.

7% to $45. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kiniksa Pharmaceuticals, Ltd.

(KNSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 19), +199. 1% 10Y return). Both have compounded well over 10 years (KNSA: +199. 1%, IMVT: +188. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KNSA is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.